FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma.
Standard
FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma. / Remke, Marc; Hielscher, Thomas; Korshunov, Andrey; Northcott, Paul A; Bender, Sebastian; Kool, Marcel; Westermann, Frank; Benner, Axel; Cin, Huriye; Ryzhova, Marina; Sturm, Dominik; Witt, Hendrik; Haag, Daniel; Toedt, Grischa; Wittmann, Andrea; Schöttler, Anna; von Bueren, André; André, O; Rutkowski, Stefan; Rutkowski, Stefan; Scheurlen, Wolfram; Kulozik, Andreas E; Taylor, Michael D; Lichter, Peter; Pfister, Stefan M.
In: J CLIN ONCOL, Vol. 29, No. 29, 29, 2011, p. 3852-3861.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma.
AU - Remke, Marc
AU - Hielscher, Thomas
AU - Korshunov, Andrey
AU - Northcott, Paul A
AU - Bender, Sebastian
AU - Kool, Marcel
AU - Westermann, Frank
AU - Benner, Axel
AU - Cin, Huriye
AU - Ryzhova, Marina
AU - Sturm, Dominik
AU - Witt, Hendrik
AU - Haag, Daniel
AU - Toedt, Grischa
AU - Wittmann, Andrea
AU - Schöttler, Anna
AU - von Bueren, André
AU - André, O
AU - Rutkowski, Stefan
AU - Rutkowski, Stefan
AU - Scheurlen, Wolfram
AU - Kulozik, Andreas E
AU - Taylor, Michael D
AU - Lichter, Peter
AU - Pfister, Stefan M
PY - 2011
Y1 - 2011
N2 - Integrated genomics approaches have revealed at least four distinct biologic variants of medulloblastoma: WNT (wingless), SHH (sonic hedgehog), group C, and group D. Because of the remarkable clinical heterogeneity of group D tumors and the dismal prognosis of group C patients, it is vital to identify molecular biomarkers that will allow early and effective treatment stratification in these non-WNT/non-SHH tumors.
AB - Integrated genomics approaches have revealed at least four distinct biologic variants of medulloblastoma: WNT (wingless), SHH (sonic hedgehog), group C, and group D. Because of the remarkable clinical heterogeneity of group D tumors and the dismal prognosis of group C patients, it is vital to identify molecular biomarkers that will allow early and effective treatment stratification in these non-WNT/non-SHH tumors.
KW - Humans
KW - Cohort Studies
KW - Child
KW - Prognosis
KW - Survival Analysis
KW - Disease-Free Survival
KW - Gene Expression Profiling
KW - Kaplan-Meier Estimate
KW - Tumor Markers, Biological/biosynthesis/genetics
KW - Brain Neoplasms/genetics/metabolism/pathology
KW - Follistatin-Related Proteins/biosynthesis/genetics
KW - Medulloblastoma/genetics/metabolism/pathology
KW - Microarray Analysis
KW - Real-Time Polymerase Chain Reaction
KW - Humans
KW - Cohort Studies
KW - Child
KW - Prognosis
KW - Survival Analysis
KW - Disease-Free Survival
KW - Gene Expression Profiling
KW - Kaplan-Meier Estimate
KW - Tumor Markers, Biological/biosynthesis/genetics
KW - Brain Neoplasms/genetics/metabolism/pathology
KW - Follistatin-Related Proteins/biosynthesis/genetics
KW - Medulloblastoma/genetics/metabolism/pathology
KW - Microarray Analysis
KW - Real-Time Polymerase Chain Reaction
M3 - SCORING: Journal article
VL - 29
SP - 3852
EP - 3861
JO - J CLIN ONCOL
JF - J CLIN ONCOL
SN - 0732-183X
IS - 29
M1 - 29
ER -